To evaluate the primary use of a laser atherectomy-thrombectomy system in patients with acute limb ischemia (ALI). A single-center retrospective review of patients presenting with ALI (14 days or less) from August 2021 to February 2024 treated primarily with a laser atherectomy-thrombectomy system (Auryon; Angiodynamics, Queensbury, New York) was performed. Technical success was defined by resolution of the acute occlusion with adequate inflow and outflow with pedal signals detectable by handheld doppler ultrasound. Primary clinical endpoints were resolution of symptoms without readmission or reintervention in the immediate post-procedure period and at 30 days with follow-up duplex ultrasound documenting patency of the treated limb. 24 procedures in 21 patients were included (mean age 60 years, M:F 1:0.7). 75% of patients (18/24) presented as Rutherford 1, 12.5% Rutherford 2A (3/24), and 12.5% Rutherford 2B (3/24), with a mean symptom duration of 4 days. Technical success was 92% (22/24) in a single session. Two technical failures required overnight adjuvant thrombolysis. 100% of patients met the immediate post-procedure endpoint, and 92% met the 30-day endpoint. There were no major device-related adverse events or deaths within 30 days, with a major amputation rate of 5%. Distal embolization occurred in 7 (29%) of cases, most of which were focal tibial emboli occurring after adjunctive plain balloon clot maceration and resolved with balloon maceration and/or additional passes of the laser atherectomy-thrombectomy system. The use of a laser atherectomy-thrombectomy system is a feasible option as a primary treatment modality for ALI.
Read full abstract